Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 12/20 | 0.46 |
| ▸ | CTSK | P43235 | 12/20 | 0.46 |
| ▸ | CTSL | P07711 | 10/20 | 0.46 |
| ▸ | CTSB | P07858 | 10/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715578 | 0.87 | CTSK (0.63) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4716709 | 0.79 | CTSK (0.57) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4717285 | 0.78 | CTSK (0.51) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4713290 | 0.75 | CTSK (0.65) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4716585 | 0.74 | CTSK (0.54) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4717337 | 0.73 | CTSK (0.52) | USP30CTSSCTSKCTSLCTSB | |
| SCHEMBL6218439 | 0.73 | CTSK (0.55) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4711735 | 0.73 | CTSK (0.63) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6217523 | 0.71 | CTSK (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL4715916 | 0.71 | CTSK (0.55) | USP30CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | claimed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | claimed |
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, CTRL, SPINT2 | USP30 446/4885MCHR1 4776/4885CTSS 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.